Search results for "Neurologia"

showing 10 items of 730 documents

Paradoxical embolism through a patent foramen ovale from central venous catheter thrombosis: A potential cause of stroke

2020

Paradoxical embolism refers to a potential condition in which an embolus arising from a venous source crosses into the systemic circulation through a right-to-left cardiac shunt causing an arterial embolism. A 39-year-old woman carrier of a central venous catheter (CVC) without evident risk factors for stroke, developed an acute right homonymous hemianopia during hemodialysis. On neuroimaging, an infarct in the territory of the left posterior cerebral artery was demonstrated. Transesophageal echocardiography revealed a patent foramen ovale (PFO) and a large fluctuating thrombus in the right atrium on the tip of the CVC, thus allowing a diagnosis of ischemic stroke from paradoxical embolism.…

Adultmedicine.medical_specialtyArterial embolismCardioembolismmedicine.medical_treatmentEmbolismForamen Ovale Patent03 medical and health sciences0302 clinical medicineParadoxical embolismEmbolusUpper Extremity Deep Vein ThrombosisInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicineThrombusStrokebusiness.industryCardiac shuntmedicine.diseasePatent foramen ovaleStrokeNeurologyPatent foramen ovaleCardiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessCentral venous catheterEchocardiography Transesophageal030217 neurology & neurosurgeryCentral venous catheterEmbolism ParadoxicalJournal of the Neurological Sciences
researchProduct

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multice…

2021

none 38 no BACKGROUND: Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). However, patients and physicians may consider discontinuing NTZ therapy due to safety or efficacy issues. The aim of our study was to evaluate the NTZ discontinuation rate and reasons of discontinuation in a large Italian population of RRMS patients. MATERIALS AND METHODS: The data were extracted from the Italian MS registry in May 2018 and were collected from 51,845 patients in 69 Italian multiple sclerosis centers. MS patients with at least one NTZ infusion in the period between June 1st 2012 to May 15th 2018 were included. Discontinuation rates at each time point were cal…

Adultmedicine.medical_specialtyDiscontinuation rateNeurologyReasons for discontinuationPopulationProgressive MultifocalRelapsing-RemittingSettore MED/26Multiple sclerosis03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingLeukoencephalopathyInternal medicineparasitic diseasesmedicineEffective treatmentHumansImmunologic FactorsMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDiscontinuation rate; Multiple sclerosis; Natalizumab; Reasons for discontinuation; Adult; Female; Humans; Immunologic Factors; Middle Aged; Natalizumab; Retrospective Studies; Leukoencephalopathy Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis Relapsing-Remittingbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyNatalizumabLeukoencephalopathy Progressive MultifocalRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Myasthenia gravis associated with Charcot-Marie-Tooth neuropathy: report of a case

1992

We report the case of a 24 year old woman who developed myasthenia gravis in the course of a mild form of Charcot-Marie-Tooth neuropathy. We describe the clinical manifestations together with the neurophysiological, pathological, serological findings and response to therapy and discuss the unusual association in the light of the relevant literature. © 1992 Masson Italia Periodici S.r.l.

Adultmedicine.medical_specialtyNeurologyResponse to therapySural nerve biopsySural NerveCharcot-Marie-Tooth DiseaseMyasthenia GravismedicineHumansReceptors CholinergicMild formPathologicalsural nerve biopsyNeuroscience (all)business.industryGeneral Neuroscienceanti-acetylcholine receptor antibodiemedicine.diseaseDermatologymyasthenia graviMyasthenia gravisSurgeryFemaleSettore MED/26 - NeurologiaNeurosurgeryNeurology (clinical)businessCharcot-Marie-Tooth neuropathy
researchProduct

Activation-Induced Rigidity in Neurologically and Cognitively Healthy Individuals Aged 18-90 Years: A Cross-Sectional Study.

2021

Background: Rigidity is a key clinical feature of Parkinson’s disease (PD), but in a very early phase of the disease it may be absent and can be enhanced through active movements of the arm contralateral to the one being tested. Objective: To evaluate in a large cohort of neurologically and cognitively healthy (NCH) subjects aged 18–90 years if activation-induced rigidity (AR) is present in all age classes, and if there are biological differences between subjects showing AR (AR+) and not showing AR (AR-). Methods: 2,228 NCH subjects categorized as young adult (18–44 years), adult (45–64 years), elderly (65–74 years), and old/oldest-old (75–90 years) were included in the analysis, and underw…

Adultmedicine.medical_specialtyParkinson's diseaseAdolescentCross-sectional studyAudiologylacunesProdromal phaseYoung AdultCellular and Molecular NeuroscienceLateral ventriclesCognitionAtrophyHumansMedicinehealthy aging subjectscaudate atrophyYoung adultAgedglobal cerebral atrophyAged 80 and overActivation-induced rigiditybusiness.industryBrainParkinson DiseaseMiddle Agedwhite matter hyperintensitiesmedicine.diseaseMagnetic Resonance ImagingHyperintensityCross-Sectional StudiesHealthy individualsSettore MED/26 - NeurologiaNeurology (clinical)Atrophybusiness
researchProduct

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

2020

IntroductionNatalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methodsThis retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the ‘Italian MS Register’. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions…

Adultmedicine.medical_specialtyPopulationmultiple sclerosisDrug Administration Schedule03 medical and health sciencesMultiple Sclerosis Relapsing-Remittingnatalizumab0302 clinical medicineNatalizumabDosing schedulesInternal medicinemedicineHumansImmunologic Factorsnatalizumab risk stratification multiple sclerosis safety effectivenessDosingeducationProportional Hazards ModelsRetrospective Studies030304 developmental biology0303 health scienceseducation.field_of_studyProportional hazards modelbusiness.industryMultiple sclerosisRetrospective cohort studyMiddle Agedmedicine.diseasePsychiatry and Mental healthTreatment OutcomeItalyTolerabilitySettore MED/26 - NeurologiaSurgeryNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct

Evidence-Based Practice Needs Stronger Prognostic Scores for the Prediction of Recurrent Stroke

2010

To the Editor: The article by Weimer et al1 is of great interest for internists and neurologists that have to prognostically stratify patients with acute or subacute cerebrovascular disease based on risk scores. However, we have to comprehend the actual and pragmatic value of the study findings for clinical practice. We previously underscored the …

Advanced and Specialized Nursingmedicine.medical_specialtySettore MED/09 - Medicina InternaEvidence-based practicebusiness.industryEvidence-based practicestrokeSettore MED/45 - Scienze Infermieristiche Generali Cliniche E Pediatricheprognostic scoreEvidence-based practice; prognostic score; stroke;Clinical PracticeRecurrent strokePhysical therapymedicineSettore MED/26 - NeurologiaNeurology (clinical)Cardiology and Cardiovascular MedicineIntensive care medicinebusinessValue (mathematics)Stroke
researchProduct

Performance cognitive in pazienti anziani sottoposti a endoarterectomia o a stenting carotideo: Studio di follow up a 12 mesi

2010

Introduction. In this study we investigated short and long-term impact of carotid endarterectomy (CEA) and carotid artery stenting (CAS) in cognitively healthy elderly subjects with severe carotid stenosis on several cognitive functions by neuropsychological evaluation before surgery and after three and twelve months. Methods. Cognition, mood and functional status were evaluated in 28 patients undergoing CEA (24 M, 4 F, 72.6 ± 5.8 years old) and in 29 patients undergoing CAS (17 M, 12 F, 75.1 ± 5.7 years old) by a broad spectrum of tests assessing mood, functional status, memory, attention, verbal fluency, visuospatial and constructional abilities. Results. No significant differences in s…

AgingArtery stentingCarotid endarterectomySettore MED/26 - NeurologiaGeriatrics and GerontologyCognitive performanceElder
researchProduct

The mysterious connection between migraine and dementia: epiphenomenon or causation? Special considerations

2022

AgingMigraine DisordersHumansmigraineSettore MED/26 - NeurologiaGeriatrics and Gerontologydementia
researchProduct

Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment

2009

Alzheimer's disease (AD) is the most common type of dementia in the elderly. Products of oxidative and nitrosative stress (OS and NS, respectively) accumulate with aging, which is the main risk factor for AD. This provides the basis for the involvement of OS and NS in AD pathogenesis. OS and NS occur in biological systems due to the dysregulation of the redox balance, caused by a deficiency of antioxidants and/or the overproduction of free radicals. Free radical attack against lipids, proteins, sugars and nucleic acids leads to the formation of bioproducts whose detection in fluids and tissues represents the currently available method for assessing oxidative/nitrosative damage. Post-mortem …

AgingPathologymedicine.medical_specialtyFree RadicalsAlzheimer’s disease Mild cognitive impairment Free radicals Nitrosative stress Oxidative stressBioenergeticsDiseaseOxidative phosphorylationmedicine.disease_causeBiochemistryPathogenesisAlzheimer DiseaseHumansMedicineDementiaMolecular BiologyFree-radical theory of agingbusiness.industryMetabolismmedicine.diseaseOxidative StressNeurologyImmunologySettore MED/26 - NeurologiaCognition DisordersReactive Oxygen SpeciesbusinessBiomarkersOxidative stressBiotechnology
researchProduct